Could a faster insulin improve blood sugar control in teens with type 1 diabetes?
NCT ID NCT06948760
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed trial tested whether a faster-acting insulin (Lyumjev) used with a special conversion factor in an automated insulin pump (Control-IQ) could improve blood sugar control in 11 adolescents with type 1 diabetes. Participants were randomly assigned to use Lyumjev with the new settings or their usual insulin (Humalog or Novolog) with optimized settings. The main goal was to see if the Lyumjev group spent more time in the target blood sugar range (70-180 mg/dL).
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lyumjev insulin (ultra-rapid-acting insulin)
What this could lead to
If successful, this could help adolescents with type 1 diabetes achieve better blood sugar control using a faster-acting insulin in an automated pump.
What could go wrong
This was a very small trial (11 participants) with no phase designation, so results may not be generalizable. Faster insulin also carries a risk of hypoglycemia.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Virginia Center for Diabetes Technology
Charlottesville, Virginia, 22903, United States